Clinical Trials Browser

Has results × Cholangiocarcinoma × regorafenib × Clear all

NCT02053376 2019-01-30

A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy

Phase 2 Completed

43 enrolled 15 charts

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma